Estimation of Total Kidney Volume in Autosomal Dominant Polycystic Kidney Disease

被引:36
|
作者
Spithoven, Edwin M. [1 ]
van Gastel, Maatje D. A. [1 ]
Messchendorp, A. Lianne [1 ]
Casteleijn, Niek F. [1 ]
Drenth, Joost P. H. [2 ]
Gaillard, Carlo A. [1 ]
de Fijter, Johan W. [3 ]
Meijer, Esther [1 ]
Peters, Dorien J. M. [4 ]
Kappert, Peter [5 ]
Renken, Remco J. [6 ]
Visser, Folkert W. [1 ]
Wetzels, Jack F. M. [7 ]
Zietse, Robert [8 ]
Gansevoort, Ron T. [1 ]
机构
[1] Univ Groningen, Univ Med Ctr Groningen, Dept Nephrol, NL-9713 AV Groningen, Netherlands
[2] Radboud Univ Nijmegen, Med Ctr, Dept Gastroenterol & Hepatol, Nijmegen, Netherlands
[3] Leiden Univ, Med Ctr, Dept Nephrol, Leiden, Netherlands
[4] Leiden Univ, Dept Human Genet, Med Ctr, NL-2300 RA Leiden, Netherlands
[5] Univ Groningen, Univ Med Ctr Groningen, Dept Radiol, NL-9713 AV Groningen, Netherlands
[6] Univ Groningen, Univ Med Ctr Groningen, Neuroimaging Ctr, Groningen, Netherlands
[7] Radboud Univ Nijmegen, Med Ctr, Dept Nephrol, Nijmegen, Netherlands
[8] Erasmus MC, Dept Nephrol, Rotterdam, Netherlands
关键词
Autosomal dominant polycystic kidney disease (ADPKD); total kidney volume (TKV); magnetic resonance imaging (MRI); estimation methods; ellipsoid; PANK; validation; ADPKD; PROGRESSION; TOLVAPTAN; TRIALS; DESIGN;
D O I
10.1053/j.ajkd.2015.06.017
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background: In autosomal dominant polycystic kidney disease (ADPKD), obtaining measured total kidney volume (mTKV) by magnetic resonance (MR) imaging and manual tracing is time consuming. Two alternative MR imaging methods have recently been proposed to estimate TKV (eTKV(ellipsoid) and eTKV(PANK)), which require less time. Study Design: Cross-sectional and longitudinal diagnostic test study. Setting & Participants: Patients with ADPKD with a wide range of kidney function and an approved T2-weighted MR image obtained at the University Medical Centers of Groningen, Leiden, Nijmegen, and Rotterdam, the Netherlands, in 2007 to 2014. Test set for assessing reproducibility, n = 10; cohort for cross-sectional analyses, n = 220; and cohort for longitudinal analyses, n = 48. Index Tests: Average times for eTKV(ellipsoid) and eTKV(PANK) were 5 and 15 minutes, respectively. Bias is defined as (mTKV - eTKV)/mTKV x 100%; precision, as one standard deviation of bias. Reference Tests: mTKV using manual tracing to calculate the area within kidney boundaries times slice thickness. Average time for mTKV was 55 minutes. Results: In the test set, intra- and intercoefficients of variation for mTKV, eTKV(ellipsoid), and eTKV(PANK) were 1.8% and 2.3%, 3.9% and 6.3%, and 3.0% and 3.4%, respectively. In cross-sectional analysis, baseline mTKV, eTKV(ellipsoid), and eTKV(PANK) were 1.96 (IQR, 1.28-2.82), 1.93 (IQR, 1.25-2.82), and 1.81 (IQR, 1.17-2.62) L, respectively. In cross-sectional analysis, bias was 0.02% +/- 3.2%, 1.4% +/- 9.2%, and 4.6% +/- 7.6% for repeat mTKV, eTKV(ellipsoid), and eTKV(PANK), respectively. In longitudinal analysis, no significant differences were observed between percentage change in mTKV (16.7% +/- 17.1%) and percentage change in eTKV(ellipsoid) (19.3% 6 16.1%) and eTKV(PANK) (17.8% +/- 16.1%) over 3 years. Limitations: Results for follow-up data should be interpreted with caution because of the limited number of patients. Conclusions: Both methods for eTKV perform relatively well compared to mTKV and can detect change in TKV over time. Because eTKV(ellipsoid) requires less time than eTKV(PANK), we suggest that this method may be preferable in clinical care. (C) 2015 by the National Kidney Foundation, Inc.
引用
收藏
页码:792 / 801
页数:10
相关论文
共 50 条
  • [41] Does hydration status influence kidney volume in autosomal dominant polycystic kidney disease?
    Naver, Signe Vinsand
    Jensen, Anja Moller
    Egfjord, Martin
    Orskov, Bjarne
    Ostergaard, Maria Grostol Ornhoj
    Blankholm, Anne Dorte
    Fallentin, Eva
    Pedersen, Michael
    Jensen, Jens Dam
    CLINICAL NEPHROLOGY, 2023, 100 (05) : 195 - 201
  • [42] Advances in Autosomal Dominant Polycystic Kidney Disease: A Clinical Keview
    Nobakht, Niloofar
    Hanna, Ramy M.
    Al-Baghdadi, Maha
    Ameen, Khalid Mohammed
    Arman, Farid
    Nobahkt, Ehsan
    Kamgar, Mohammad
    Rastogi, Anjay
    KIDNEY MEDICINE, 2020, 2 (02) : 196 - 208
  • [43] Increases in kidney volume in autosomal dominant polycystic kidney disease can be detected within 6 months
    Kistler, Andreas D.
    Poster, Diane
    Krauer, Fabienne
    Weishaupt, Dominik
    Raina, Shagun
    Senn, Oliver
    Binet, Isabelle
    Spanaus, Katharina
    Wuethrich, Rudolf P.
    Serra, Andreas L.
    KIDNEY INTERNATIONAL, 2009, 75 (02) : 235 - 241
  • [44] Recognizing and treating autosomal dominant polycystic kidney disease
    Uko, Chigozie G.
    NURSE PRACTITIONER, 2020, 45 (11) : 41 - 47
  • [45] An update on treatments for autosomal dominant polycystic kidney disease
    Patel, Suhani Janak
    Sadowski, Catherine K.
    JAAPA-JOURNAL OF THE AMERICAN ACADEMY OF PHYSICIAN ASSISTANTS, 2023, 36 (06): : 11 - 16
  • [46] Pharmacologic Management of Autosomal Dominant Polycystic Kidney Disease
    Ackley, William
    Dahl, Neera K.
    Park, Meyeon
    ADVANCES IN KIDNEY DISEASE AND HEALTH, 2023, 30 (03): : 228 - 235
  • [47] Imaging for the prognosis of autosomal dominant polycystic kidney disease
    Bae, Kyongtae T.
    Grantham, Jared J.
    NATURE REVIEWS NEPHROLOGY, 2010, 6 (02) : 96 - 106
  • [48] Targeted Therapies for Autosomal Dominant Polycystic Kidney Disease
    Stayner, Cherie
    Brooke, Darby G.
    Bates, Michael
    Eccles, Michael R.
    CURRENT MEDICINAL CHEMISTRY, 2019, 26 (17) : 3081 - 3102
  • [49] Autosomal dominant polycystic kidney disease: updated perspectives
    Rastogi, Anjay
    Ameen, Khalid Mohammed
    Al-Baghdadi, Maha
    Shaffer, Kelly
    Nobakht, Niloofar
    Kamgar, Mohammad
    Lerma, Edgar, V
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2019, 15 : 1041 - 1052
  • [50] Everolimus in Patients with Autosomal Dominant Polycystic Kidney Disease
    Walz, Gerd
    Budde, Klemens
    Mannaa, Marwan
    Nuernberger, Jens
    Wanner, Christoph
    Sommerer, Claudia
    Kunzendorf, Ulrich
    Banas, Bernhard
    Hoerl, Walter H.
    Obermueller, Nicholas
    Arns, Wolfgang
    Pavenstaedt, Hermann
    Gaedeke, Jens
    Buechert, Martin
    May, Christoph
    Gschaidmeier, Harald
    Kramer, Stefan
    Eckardt, Kai-Uwe
    NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (09) : 830 - 840